secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monopar Therapeutics (MNPR)
CIK:        0001645469
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001654954-23-006120
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monopar Q1 net loss $2.4M; camsirubicin dose-escalation continues; Validive trial discontinued
--------------------------------------------------------------------------------

- Net loss of $2.4M ($0.19/share) for Q1 2023, vs $2.5M ($0.19/share) in Q1 2022.
- Cash, equivalents and short-term investments $11.7M as of March 31, 2023; runway through June 2024.
- Camsirubicin Phase 1b enrolling 5th dose cohort (650 mg/m²); no drug-related cardiotoxicity observed to date.
- Validive Phase 2b/3 VOICE trial discontinued after DSMB found it did not meet 15% efficacy threshold.
- MNPR-101 RIT preclinical studies show high tumor uptake; FIH imaging study targeted by end of 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645469/000165495423006120/0001654954-23-006120-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645469/000165495423006120/mnpr_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-23-006120

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer